MC

554.5

+4.62%↑

SANES

10.724

+1.42%↑

BBVA

19.81

+0.69%↑

BNP

94.58

+0.85%↑

CABK

10.96

+3.01%↑

MC

554.5

+4.62%↑

SANES

10.724

+1.42%↑

BBVA

19.81

+0.69%↑

BNP

94.58

+0.85%↑

CABK

10.96

+3.01%↑

MC

554.5

+4.62%↑

SANES

10.724

+1.42%↑

BBVA

19.81

+0.69%↑

BNP

94.58

+0.85%↑

CABK

10.96

+3.01%↑

MC

554.5

+4.62%↑

SANES

10.724

+1.42%↑

BBVA

19.81

+0.69%↑

BNP

94.58

+0.85%↑

CABK

10.96

+3.01%↑

MC

554.5

+4.62%↑

SANES

10.724

+1.42%↑

BBVA

19.81

+0.69%↑

BNP

94.58

+0.85%↑

CABK

10.96

+3.01%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

183 4.24

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

175.6

Max

184.05

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-28M

64M

Pardavimai

67M

772M

P/E

Sektoriaus vid.

63.37

36.642

Pelnas, tenkantis vienai akcijai

0.94

Pelno marža

9.097

Darbuotojai

10,134

EBITDA

555M

772M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+34.05% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-23

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.6B

17B

Ankstesnė atidarymo kaina

178.76

Ankstesnė uždarymo kaina

183

Naujienos nuotaikos

By Acuity

28%

72%

68 / 443 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-19 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

2026-02-19 23:39; UTC

Įsigijimai, susijungimai, perėmimai

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

2026-02-19 23:38; UTC

Uždarbis

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

2026-02-19 23:37; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustment -- Market Talk

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

2026-02-19 23:34; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

2026-02-19 23:33; UTC

Uždarbis

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

2026-02-19 22:13; UTC

Rinkos pokalbiai

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

2026-02-19 22:08; UTC

Uždarbis

Fairfax Financial 4Q Rev $8.11B >FFH.T

2026-02-19 22:07; UTC

Uždarbis

Eldorado Gold 4Q EPS $1.19 >ELD.T

2026-02-19 22:06; UTC

Uždarbis

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Adj EPS 63c >ELD.T

2026-02-19 22:05; UTC

Uždarbis

Eldorado Gold 4Q Rev $577.2M >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

2026-02-19 22:04; UTC

Uždarbis

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

2026-02-19 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-19 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-19 21:43; UTC

Uždarbis

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

2026-02-19 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

2026-02-19 21:42; UTC

Uždarbis

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

2026-02-19 21:41; UTC

Uždarbis

Correct: St Barbara 1H Net Loss A$249,000

2026-02-19 21:40; UTC

Uždarbis

St Barbara 1H Net Loss A$249 Million

2026-02-19 21:39; UTC

Uždarbis

Perseus Mining Reaffirms FY26 Production, AISC Guidance

2026-02-19 21:37; UTC

Uždarbis

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

2026-02-19 21:37; UTC

Uždarbis

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

34.05% į viršų

12 mėnesių prognozė

Vidutinis 235.86 EUR  34.05%

Aukščiausias 260 EUR

Žemiausias 210 EUR

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

3

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

68 / 443 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat